Trial results

Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

NCT07866066 on ClinicalTrials.gov · last registry update 2026-10-08

An unusually large phase 3: 1,300 participants, more than double the 424 typical for the stage. Due to report 4 September 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Amgen

Sponsor type

Industry

Enrollment

1,300

Started

2026-11-02

Primary completion

2028-09-04 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.